Nakamura T, Hashimoto I, Sawada Y, Mikami J, Yoshimoto M, Nishindai H, Nakanishi Y, Kasai Y
Jpn J Antibiot. 1985 May;38(5):1178-94.
Cefminox sodium (CMNX, MT-141), a new semisynthetic cephamycin, having marked resistance to beta-lactamase, and a broad spectrum of antibacterial activity against various bacterial species, including Haemophilus influenzae, Serratia marcescens and Citrobacter freundii, CMNX has higher activity in vivo than in vitro. For therapeutic purpose, CMNX was given in a daily dose of 0.5 g (0.5 g X 1) to 2 g (1 X 2) by intravenous drip infusion for 4 to 8 days to 24 cases with acute peritonitis (17 cases with acute appendicitis, 1 with localized peritonitis after gastrectomy, 1 with diffuse peritonitis due to perforative duodenal ulcer and 5 with panperitonitis due to intestinal obstruction). The clinical response was rated excellent in 9 cases, good in 14 cases and fair in 1 case and poor in none. No adverse effect was observed. There were 29 strains isolated organisms included 12 Escherichia coli, some Enterococcus faecalis and Pseudomonas aeruginosa. These isolated organisms were eradicated after CMNX treatment, except a strain of E. faecalis was decreased. In 19 cases of them, 16 cases with acute peritonitis due to acute appendicitis and 3 cases with acute panperitonitis due to intestinal obstruction, CMNX was administered intravenously in a dose of 1 g (1 case was 0.5 g) before or during the operation, and tissue specimens and body fluids samples were taken during the operation. CMNX concentration was determined to a bioassay with Escherichia coli NIHJ or Vibrio vercolans ATCC 8461 as the test organisms. CMNX concentrations in purulent ascites were 47.2 +/- 38.5 micrograms/ml (n = 23), those in infected appendix wall were 32.2 +/- 21.7 micrograms/g (n = 16), that in pus in appendix were 22.1 +/- 24.3 micrograms/ml (n = 8) and that in other non infected tissues were 24.3 +/- 22.0 micrograms/g (n = 8). CMNX concentrations in infected tissues were higher than the non infected tissues. In the 3 cases with empyemic appendicitis, CMNX levels in pus in appendix were more higher than that in appendix wall itself. Therefore, CMNX sodium appears to be a very useful drug when used for chemotherapy on acute peritonitis.
头孢米诺钠(CMNX,MT - 141)是一种新型半合成头孢菌素,对β - 内酰胺酶具有显著抗性,对包括流感嗜血杆菌、粘质沙雷氏菌和弗氏柠檬酸杆菌在内的多种细菌具有广谱抗菌活性。CMNX在体内的活性高于体外。为了治疗目的,对24例急性腹膜炎患者(17例急性阑尾炎、1例胃切除术后局限性腹膜炎、1例十二指肠溃疡穿孔所致弥漫性腹膜炎和5例肠梗阻所致全腹膜炎),以每日0.5g(0.5g×1)至2g(1×2)的剂量通过静脉滴注给药4至8天。临床反应评定为优9例、良14例、中1例,无差的病例。未观察到不良反应。分离出29株菌,包括12株大肠杆菌、一些粪肠球菌和铜绿假单胞菌。经CMNX治疗后,这些分离菌均被清除,除1株粪肠球菌数量减少。其中19例,16例急性阑尾炎所致急性腹膜炎和3例肠梗阻所致急性全腹膜炎,在手术前或手术期间静脉给予CMNX剂量为1g(1例为0.5g),并在手术期间采集组织标本和体液样本。以大肠杆菌NIHJ或溶藻弧菌ATCC 8461作为测试菌进行生物测定来确定CMNX浓度。脓性腹水中CMNX浓度为47.2±38.5μg/ml(n = 23),感染阑尾壁中为32.2±21.7μg/g(n = 16),阑尾脓液中为2 .. 1±24.3μg/ml(n = 8),其他未感染组织中为24.3±22.0μg/g(n = 8)。感染组织中的CMNX浓度高于未感染组织。在3例脓性阑尾炎病例中,阑尾脓液中的CMNX水平比阑尾壁本身的水平高得多。因此,头孢米诺钠用于急性腹膜炎的化疗时似乎是一种非常有用的药物。